Bicara Therapeutics BCAX Q1 2026 Earnings ClinicalStage Biotech Reports WiderthanExpected Loss Shares Rise VRCA Q1 2026 Earnings EPS Misses Estimates as Commercialization Costs Weigh on Results PEPG Q1 2026 Earnings NarrowerthanExpected Loss Drives Optimism Despite Revenue Absence ATNM Q1 2026 Earnings EPS Beat Highlights Cost Discipline as Pipeline Advances NOTE Q1 2026 Earnings EPS Surprises to the Upside Despite Revenue Headwinds BRAG Q1 2026 Earnings EPS Surpasses Estimates Amid Prudent Cost Controls